ArriVent BioPharma, Inc. AVBP 深 沪
等待开盘 05-21 09:30:00 美东时间
27.22
+1.070
+4.09%
华盛通- 最 高27.35
- 今 开26.15
- 成交量 45.44万股
- 最 低 26.06
- 昨 收 26.15
- 总市值 12.68亿
- 52周最高 32.14
- 市盈率 静 --
- 换手率 0.98%
- 52周最低 16.10
- 委 比 20.48%
- 总股本 4657.49万
- 历史最高 36.37
- 量 比 1.36
- 振 幅 4.93%
- 历史最低 14.35
- 每 手 1
- 风险率 3.25%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅257.14%！瑞杰金融上调InflaRx目标价至9美元，评级升至"强烈买入"
今日重点评级关注：瑞杰金融：上调InflaRx评级至"强烈买入"，目标价从7美元升至9美元；巴克莱：维持Orchestra BioMed Hldgs"超配"评级，目标价从12美元升至13美元
05-14 14:32
Citigroup Maintains Buy on ArriVent BioPharma, Lowers Price Target to $43
Citigroup analyst Yigal Nochomovitz maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and lowers the price target from $45 to $43.
05-14 02:46
ArriVent Biopharma Launches $250M At-The-Market Common Stock Offering Through Jefferies
$250,000,000Common StockWe have entered into an Open Market Sale AgreementSM (the sales agreement) with Jefferies LLC (Jefferies), as our sales agent, relating to the shares of our common stock offered by this prospectus
05-12 04:52
ArriVent BioPharma Q1 EPS $(0.96) Misses $(0.86) Estimate
ArriVent BioPharma (NASDAQ:AVBP) reported quarterly losses of $(0.96) per share which missed the analyst consensus estimate of $(0.86) by 11.63 percent. This is a 49.47 percent increase over losses of $(1.90) per share
05-12 04:12
美股大行评级 | 潜在涨幅33%！大小摩等9家大行上调英特尔目标价；Popular、都福集团、联合太平洋、联合租赁等获多家大行上调评级
今日重点评级关注：瑞银：维持SS&C科技"买入"评级，目标价从112美元升至115美元；Piper Sandler：维持儒博实业"超配"评级，目标价从530美元升至540美元
04-27 14:04
Citigroup Maintains Buy on ArriVent BioPharma, Raises Price Target to $45
Citigroup analyst Yigal Nochomovitz maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and raises the price target from $33 to $45.
04-24 22:04
Vicor, AXT And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
US stock futures rise, Vicor Corp shares dip 2.2% in pre-market trading after beating earnings and sales estimates. Other stocks also decline.
04-21 20:03
美股大行评级 | 瑞穗上调MongoDB至"跑赢大市"，目标价从290美元升至325美元；麦格理下调小鹏评级至"中性" 目标价从24美元降至19美元
今日重点评级关注：HC Wainwright & Co.：维持Perspective Therapeutics"买入"评级，目标价从12美元升至13美元；Litchfield Hills：维持Star Equity Holdings"买入"评级，目标价从21美元升至28美元
03-24 10:07
ArriVent BioPharma To Reveal Two Preclinical Posters On The EGFR Inhibitor Firmonertinib And On the Novel Dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 At The 2026 AACR Annual Meeting
Unique structural features of firmonertinib enhance binding and activity against EGFR mutant proteins including ex20ins mutant proteins in cell lines and NSCLC animal modelsSuperior anti-tumor activity of ARR-002 in
03-18 05:19
美股大行评级 | 潜在涨幅101%！甲骨文获花旗升目标价至320美元，维持"买入"评级
今日重点评级关注：Freedom Capital Markets：维持LifeMD"买入"评级，目标价从8美元升至10美元；Chardan Capital：维持Opus Genetics"买入"评级，目标价从9美元升至11美元
03-13 09:59
